ArticleScience advances2024
Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes.
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Comparative proteomics of human naso-oropharyngeal swabs from COVID19 patients for identification of potential biomarker candidates.Biochemistry and biophysics reports · 2026Article
- The Acute Respiratory Distress Syndrome (ARDS): epidemiology, etiology, molecular mechanisms, diagnosis and therapeutic strategies.Molecular biomedicine · 2026Review
- Virus reactivation in acute and long COVID-19.Nature · 2026Article
- AI-driven big data analysis and predictive modeling of infectious disease immunity: from correlates to causal, multiscale understanding.Archives of microbiology · 2026Review
- Plasma multi-omics profiling unravels molecular alterations and biomarker panels during recovery from severe coronavirus disease 2019: a pilot study.BMC infectious diseases · 2026Article
- Antibody profiling and plasma proteomics in SARS-CoV-2 infection: a pilot study.Scientific reports · 2026Article
- Impact of Variations in Commercial Standard Operating Procedure on Plasma Proteome Recovery.Journal of proteome research · 2026Article
- Viral Prognosis Using Proteomics.Advances in experimental medicine and biology · 2026Review
- Recombinant RBD-based subunit vaccines incorporating high-frequency mutation sites elicit cross-immunity and robust protection against SARS-CoV-2.Frontiers in microbiology · 2026Article
- Cross-platform clinical proteomics using the Charité open standard for plasma proteomics (OSPP).Nature communications · 2025Article
- Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Considering Measurement Time and Depth in diaPASEF Plasma Proteomics.Journal of proteome research · 2025Article
- Circulating histones as clinical biomarkers in critically ill conditions.FEBS letters · 2025Review
- Pre-analytical drivers of bias in bead-enriched plasma proteomics.EMBO molecular medicine · 2025Article
- Bioinformatics analysis of the proteome in the pathway of complement and coagulation cascades in COVID-19: discovering potential biomarkers of FGB and SERPINA5.BMC infectious diseases · 2025Article
- Technical Evaluation of Plasma Proteomics Technologies.Journal of proteome research · 2025Article
- Utility of Protein Markers in COVID-19 Patients.International journal of molecular sciences · 2025Review
- Patients Hospitalized with COVID-19 Demonstrate Distinct Plasma Cytokine and Chemokine Concentrations in vivo and TLR-Mediated Cytokine and Chemokine Production in Whole Blood in vitro.Journal of innate immunity · 2025Article
- The Circulating Proteome─Technological Developments, Current Challenges, and Future Trends.Journal of proteome research · 2024Article
- Chronic Viral Reactivation and Associated Host Immune Response and Clinical Outcomes in Acute COVID-19 and Post-Acute Sequelae of COVID-19.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is characterized by highly heterogeneous manifestations ranging from asymptomatic cases to death for still incompletely understood reasons. As part of the IMmunoPhenotyping Assessment in a COVID-19 Cohort study, we mapped the plasma proteomes of 1117 hospitalized patients with COVID-19 from 15 hospitals across the United States. Up to six samples were collected within ~28 days of hospitalization resulting in one of the largest COVID-19 plasma proteomics cohorts with 2934 samples. Using perchloric acid to deplete the most abundant plasma proteins allowed for detecting 2910 proteins. Our findings show that increased levels of neutrophil extracellular trap and heart damage markers are associated with fatal outcomes. Our analysis also identified prognostic biomarkers for worsening severity and death. Our comprehensive longitudinal plasma proteomics study, involving 1117 participants and 2934 samples, allowed for testing the generalizability of the findings of many previous COVID-19 plasma proteomics studies using much smaller cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.